Mar 26, 2026 9:27am EDT Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient
Mar 17, 2026 7:47am EDT Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance
Mar 04, 2026 10:25am EST Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds
Mar 04, 2026 7:00am EST Can-Fite’s Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study
Feb 17, 2026 7:00am EST Can-Fite Announces Scientific Breakthrough Publication Demonstrating Anti-Obesity Effect of Namodenoson
Feb 09, 2026 7:00am EST Can-Fite: Receives Canadian Patent Allowance for Namodenoson as an Anti-Obesity Therapy
Feb 05, 2026 7:00am EST Can-Fite: Patient with Decompensated Liver Cirrhosis Successfully Undergoes Liver Transplantation Following Treatment with Namodenoson
Jan 20, 2026 7:00am EST Can-Fite Completes Patient Enrollment in Phase 2a Pancreatic Cancer Study of Namodenoson
